Skip to main content

Table 4 Association of baseline FT4 with predicted risks for future outcomes of incident CKD

From: Thyroid hormones associate with risk of incident chronic kidney disease and rapid decline in renal function: a prospective investigation

  Predicted risks for future outcomes of incident CKD
Moderately increased risk Combined high and very high increased risk
Case/number (%) 177/2103 (8.4) 21/2103 (1.0)
Each 1-pmol/l increase in FT4
 Model 1 1.12 (1.04–1.21) 1.18 (1.05–1.34)
 Model 2 1.11 (1.03–1.19) 1.22 (1.06–1.41)
Each 1-tertile increase in FT4
 Model 1 1.33 (1.09–1.61) 2.73 (1.41–5.27)
 Model 2 1.30 (1.06–1.59) 2.61 (1.32–5.16)
  1. Model 1: adjusted for age, sex, BMI at baseline
  2. Model 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension status, current smoking and drinking status, use of antihypertensive drugs, use of antidiabetic drugs, urinary ACR, eGFR, TPOAb and TGAb at baseline
  3. Data are odds ratios (95% confidence intervals), calculated by using multinomial logit regression analysis, referenced to low risk of prognosis of incident CKD
  4. ACR albumin-to-creatinine ratio, BMI body mass index, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, FT4 free thyroxine, HDL-c high-density lipoprotein cholesterol, TPOAb thyroid peroxidase antibody, TGAb thyroglobulin antibody